1 Result

People

  1. Cordon-Cardo
    Cordon-Cardo
  2. Drobnjak
    Drobnjak
  3. Kelly
    Kelly
  4. Morris
    Morris
  5. Rosen
    Rosen
  6. Scher
    Scher
  7. Siedlecki
    Siedlecki
  8. Slovin
    Slovin
  9. Swanson
    Swanson
  10. Terry
    Terry

Groups

  1. Breast Medicine Service (1)
  2. Department of Medicine (1)
  3. GSK Faculty (1)
  4. Genitourinary Oncology Service (1)
  5. Hematologic Malignancies, Division of (1)
  6. Molecular Pharmacology and Chemistry Program Faculty (1)
  7. Sloan Kettering Institute Faculty (1)
  8. Solid Tumor Oncology Division (1)
  1. "priority journal"
  2. "Neal Rosen"
  3. "Karen Siedlecki"
Formats
  1. Journal Article (1)
Groups
  1. Breast Medicine Service (1)
  2. Department of Medicine (1)
  3. GSK Faculty (1)
  4. Genitourinary Oncology Service (1)
  5. Hematologic Malignancies, Division of (1)
  6. Molecular Pharmacology and Chemistry Program Faculty (1)

More Groups

People
  1. Carlos Cordon-Cardo (1)
  2. Howard Scher (1)
  3. Karen Siedlecki (1)
  4. Kathryn Terry (1)
  5. Marija Drobnjak (1)
  6. Michael Morris (1)

More People

Years
  1. 2002 (1)
Publications
  1. Clinical Cancer Research (1)
Publishers
  1. American Association for Cancer Research (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Journal Article

    Morris, M. J.; Tong, W. P.; Cordon-Cardo, C.; Drobnjak, M.; Kelly, W. K.; Slovin, S. F.; Terry, K. L.; Siedlecki, K.; Swanson, P.; Rafi, M.; more...
    Clinical Cancer Research (2002)

    Fulltext@MSK | Save